Wheels Up Experience (UP) is back in focus after receiving a NYSE notice about its sub US$1 share price, outlining cost reduction plans and expanding its Delta Air Lines partnership to let members book Delta flights through its portal.
See our latest analysis for Wheels Up Experience.
The NYSE notice and the expanded Delta partnership come after a sharp rebound in the 1 day share price return of 46.58% and a 7 day share price return of 44.45%. However, the 1 year total shareholder return...
Xencor recently outlined its 2026 priorities and advancement milestones for its clinical-stage XmAb drug portfolio, highlighting progress across oncology and autoimmune programs, including early anti-tumor activity and tolerability for its lead T-cell engagers.
An important takeaway for investors is Xencor’s expectation that its current cash resources should fund research and operations through 2028, supporting multiple planned pivotal studies without near-term financing guidance.
We’ll now...
UroGen Pharma (URGN) shares are in focus after the company reported that its bladder cancer therapy ZUSDURI now has a permanent J code (J9282), effective January 1, 2026, simplifying reimbursement.
See our latest analysis for UroGen Pharma.
The J code news comes after a strong run for UroGen Pharma, with a 90 day share price return of 24.06% and a 1 year total shareholder return of 116.01%, signaling that momentum has been building rather than fading.
If this kind of healthcare access story...
In recent months, TopBuild has benefited from a construction surge, with its installer-distributor model capturing value from both material markups and installation services, helping it consistently exceed earnings estimates.
This dual-revenue approach has allowed TopBuild to enhance margins while some manufacturers face cost pressure, highlighting how its business model can extract more value from robust building activity.
We'll now examine how TopBuild's installer-distributor model,...
In January 2026, Rigel Pharmaceuticals issued full-year 2026 earnings guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenue.
This fresh guidance gives investors a clearer view of how management currently sees the balance between core product sales and partnership-driven contract income.
We’ll now consider how Rigel’s new 2026 revenue guidance,...
First Watch Restaurant Group has recently expanded its New England footprint by opening a 3,100-square-foot restaurant on Boylston Street in Boston’s Back Bay, featuring seating for 130 guests, an outdoor patio, a full bar and locally inspired artwork, alongside its made-to-order breakfast, brunch and lunch menu and Project Sunrise coffee.
This Back Bay opening highlights First Watch’s push into dense urban, experience-focused neighborhoods, adding a new proof point for its daytime-only...
Artisan Partners Asset Management reported preliminary assets under management of US$180.80 billion as of November 30, 2025, and disclosed that annual fund distributions and a US$2.70 billion redemption by a non‑U.S. institutional client in early December affected these figures.
This combination of income and capital gains distributions with a large, pension‑linked institutional outflow highlights how client concentration and market structure can quickly reshape Artisan’s asset base.
We’ll...
Sify Technologies (NasdaqCM:SIFY) has just posted its Q3 2026 numbers, with revenue of ₹11,596 million and a net loss, excluding extra items, of ₹329 million, setting the tone for how investors assess its current footing. The company has seen quarterly revenue move from ₹10,491 million in Q3 2025 to ₹11,596 million in Q3 2026, while trailing 12 month revenue stands at ₹42,550.58 million against a trailing 12 month net loss of ₹1,569.96 million, which keeps the spotlight firmly on its margin...
In recent days NovaBay Pharmaceuticals has attracted intense trading interest as it pursued asset sales, preferred stock designations, and leadership changes instead of outright liquidation, while working to maintain its NYSE American listing.
This combination of corporate restructuring steps and renewed focus on preserving the public listing has turned the company into a speculative focal point for investors reviewing its remaining options.
We’ll now examine how this shift toward...
Ligand Pharmaceuticals recently updated its long-term outlook, projecting 40% royalty revenue growth for 2026 and a 23% compound annual growth rate through 2030, supported by products including Filspari, Ohtuvayre and Capvaxive.
The company also highlighted more than US$1.00 billion in deployable capital for new royalty deals targeting unmet medical needs, underlining its capacity to expand the portfolio further.
We’ll now examine how this upgraded royalty growth outlook, underpinned by...
Worthington Steel (WS) is back in focus after its latest Form 10-Q highlighted financial and operational performance tied to automotive demand, the Sitem Group acquisition in Europe, and increased use of AI and technology.
See our latest analysis for Worthington Steel.
The recent Form 10-Q, the Sitem Group acquisition in Europe and the push into AI supported operations are all landing against a share price of $36.93, with a 90 day share price return of 20.41% and a 1 year total shareholder...
